Please ensure Javascript is enabled for purposes of website accessibility

2 Upcoming Catalysts for Amarin

By Max Macaluso - Apr 24, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two important events that Amarin investors need to watch.

Biotech Amarin (AMRN 19.20%) has slide more than 20% since launching its hypertriglyceridemia drug Vascepa in January. The company's market value has dropped following months of indecision regarding the drug's exclusivity status and question marks over the drug's launch. As the stock continues to be hotly debated, there are two catalysts in particular that investors should watch. Health-care analyst Max Macaluso discusses each in the following video.

Editor's Note: At 1:00, the speaker meant to say eight months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
$1.49 (19.20%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.